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ABSTRACT 
Among the ocular dosage forms, the physiological and anatomical constraints put forth by the eye is a significant challenge to the 
pharmaceutical scientists and researchers to target drugs to the posterior segment of the eye, prolong their contact time with the ocular surface 
and sustained release. Hence novel drug delivery strategies and formulations are to be developed and explored which will overcome the ocula r 
constraints and provide better patient compliance. At present, various novel and controlled drug delivery systems are being d eveloped in order 
to attain better ocular bioavailability, sustained action of ocular drugs as well as good patient compliance. Ocular insert is an example of such 
delivery system. These are sterile preparations, with a thin, multilayered, drug-impregnated, solid or semisolid consistency devices placed into 
cul-de-sac or conjunctiva sac of the eye. Ocular inserts are an alternative approach to overcome the problems associated with conventional 
ocular dosage forms like solutions, suspensions, ointments, etc. The article hereunder gives a detailed idea about the classification, mechanism 
of action, formulation, pros and cons; evaluation and future trends of ocular inserts.  
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INTRODUCTION:  
Ocular drug delivery is one of the most fascinating and 
challenging tasks faced by the Pharmaceutical researchers. 
But to obtain and maintain a therapeutic level at the site of 
action for prolonged period of time is one of the major 
barriers of ocular medication. The anatomy, physiology and 
biochemistry of the eye render this organ exquisitely 
impervious to foreign substances. The challenge to the 
formulator is to circumvent the protective barriers of the 
eye without causing permanent tissue damage. The 
development of newer, more sensitive diagnostic techniques 
and therapeutic agents render urgency to the development 
of maximum successful and advanced ocular drug delivery 
systems1. One of the new classes of drug delivery systems, 
polymeric film ocular drug delivery systems/ocular inserts, 
which are gaining worldwide accolade, release drugs at a 
pre-programmed rate for a longer period by increasing the 
pre-corneal residence time2. 
Ocular inserts are defined as sterile preparations, with a 
thin, multilayered, drug-impregnated, solid or semisolid 
consistency devices placed into cul-de-sac or sac of 
conjunctiva and whose size and shape are especially 
designed for ophthalmic application. These inserts are 
placed in lower fornix and less frequently, in upper fornix or 
on the cornea. They are usually made up of polymeric 
vehicle containing drug and are mainly used for topical 
therapy2,3. They are composed of a polymeric support 
containing or not drug(s), the latter being incorporated as 
dispersion or a solution in the polymeric support 4. 
Ocular inserts offer an attractive alternative approach to the 
difficult problem of limited pre-corneal drug residence time. 
Disposition and elimination of a therapeutic agent depends 
on the physicochemical properties as well as the relevant 
ocular anatomy and physiology. The successful design of a 
drug delivery system, therefore, requires a complete 
knowledge of the drug moiety and the constraints to 
delivery offered by the ocular route of administration. The 
main objective of the ophthalmic inserts is to increase the 
contact time between the preparation and the conjunctival 
tissue, to ensure a sustained release suited for topical or 
systemic treatment 4,5,6,7,8. 
BACKGROUND:  
The history of ocular inserts dates back to the 19th century 
when solid medications which consisted of squares of dry 
filter paper, previously impregnated with dry solutions (e.g., 
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atropine sulphate, pilocarpine hydrochloride) were used as 
ocular inserts. Small sections were cut and applied under the 
eyelid. Later, the precursors of the present soluble inserts 
called lamellae were developed which consisted of 
glycerinated gelatin containing different ophthalmic drugs. 
Glycerinated gelatin ‘lamellae’ were present until the first 
half of the present century in official compendia. However, 
the use of lamellae ended when more stringent 
requirements for sterility of ophthalmic preparations were 
enforced. Nowadays, growing interest is observed for 
ophthalmic inserts as demonstrated by the increasing 
number of publications in this field in the recent years 2. 
DESIRED FEATURES OF OCULAR INSERTS9: 
 Should be bio stable & biocompatible with the tissues 
of the eye. 
 Should be nontoxic & non carcinogenic. 
 Should be retrievable & should release the drug at a 
constant rate.  
 Should be non-immunogenic as well as non-mutagenic. 
 Should possess a good mechanical strength. 
 Should be free from drug leakage. 
 Should be easily sterilizable. 
 Should be easy and inexpensive to manufacture. 
 Should be applicable for a good variety of drugs. 
 Should not interfere with the vision and oxygen 
permeability. 
MECHANISM OF DRUG RELEASE FROM OCULAR 
INSERTS: 
The drug release from the ocular inserts takes place by 
follows mechanisms:  
A. Diffusion  
B. Osmosis  
C. Bio-erosion.  
A. Diffusion: In the diffusion mechanism, the drug is 
released continuously at a controlled rate through the 
membrane into the tear fluid, if the insert is formed of a solid 
non- erodible body with pores and dispersed drug. The 
release of drug can take place through the pores via 
diffusion. Controlled release can be further regulated by 
gradual dissolution of solid dispersed drug within this 
matrix as a result of inward diffusion of aqueous 
solutions10,11. 
In a soluble device, true dissolution occurs mainly through 
polymer swelling. In swelling controlled devices, the active 
agent is homogeneously dispersed in a glassy polymer. Since 
glassy polymers are essentially drug impermeable, no 
diffusion through the dry matrix occurs. When the insert is 
placed in the eye, water from the tear fluid begins to 
penetrate the matrix, then swelling and consequently 
polymer chain relaxation and drug diffusion take place. The 
dissolution of the matrix, which follows the swelling process, 
depends on polymer structure; linear amorphous polymers 
dissolve much faster than cross-linked or partially 
crystalline polymers. Release from these devices follows in 
general fickian 'square root of time' kinetics; however, in 
some instances, case II transport, zero order kinetics has 
been observed12.  
B. Osmosis: In the osmosis mechanism, the insert comprises 
a transverse impermeable elastic membrane dividing the 
interior of the insert into two compartments; the first 
compartment is bounded by a semipermeable membrane 
and the impermeable elastic membrane and the second 
compartment is bounded by an impermeable material and 
the elastic membrane. There is a drug release aperture in the 
impermeable wall of the insert. The first compartment 
contains a solute which cannot pass through the semi-
permeable membrane and the second compartment 
provides a reservoir for the drug which again is in liquid or 
gel form. When the insert is placed in the aqueous 
environment of the eye, water diffuses into the first 
compartment and stretches the elastic membrane to expand 
the first compartment and contract the second 
compartment, so that the drug is forced through the drug 
release aperture11.  
Bio-erosion: In the Bio-erosion mechanism, the 
configuration of the body of the insert is constituted from a 
matrix of bio-erodible material in which the drug is 
dispersed. Contact of the insert with tear fluid results in 
controlled sustained release of the drug by bio-erosion of the 
matrix. The drug may be dispersed uniformly throughout the 
matrix but it is believed that a more controlled release is 
obtained if the drug is superficially concentrated in the 
matrix. In truly erodible devices, the rate of drug release is 
controlled by a chemical or enzymatic hydrolytic reaction 
that leads to polymer solubilization, or degradation to 
smaller, water-soluble molecules. These polymers may 
undergo bulk or surface hydrolysis. Erodible inserts 
undergoing surface hydrolysis can display zero order release 
kinetics; provided that the devices maintain a constant 
surface geometry and that the drug is poorly water soluble13. 
ADVANTAGES OF OCULAR INSERTS 2, 10, 14, 15: 
Ocular inserts offer several advantages, which can be 
summarized as follows: 
 Increase in ocular residence, hence a prolonged drug 
activity and a higher bioavailability with respect to 
standard vehicles; 
 Possibility of drug release at a slow, constant rate; 
 Accurate dosing (contrary to eye drops that can be 
improperly instilled by the patient and are partially 
lost after administration, each insert can be made to 
contain a precise dose which is fully retained at the 
administration site); 
 Reduction of systemic absorption (which occurs freely 
mainly with eye drops via the naso-lacrimal duct and 
nasal mucosa); 
 Better patient compliance, resulting from a reduced 
frequency of administration and a lower incidence of 
visual and systemic side-effects; 
 Possibility of targeting internal ocular tissues through 
non-corneal (conjunctival scleral) routes; 
 Increased shelf life with respect to aqueous solutions; 
 Exclusion of preservatives, thus reducing the risk of 
sensitivity reactions; 
 Possibility of incorporating various novel chemical/ 
technological approaches like pro-drugs, muco-
adhesives, permeation enhancers, micro-particulates, 
salts acting as buffers, etc; 
 Reproducibility of release kinetics; 
 Sterility. 
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DISADVANTAGES OF OCULAR INSERTS2,14: 
The disadvantages of ocular inserts are as follows: 
 A capital disadvantage of ocular inserts resides in their 
‘solidity’, i.e., in the fact that they are felt by the (often 
oversensitive) patients as an extraneous body in the 
eye. This may constitute a formidable physical and 
psychological barrier to user acceptance and 
compliance; 
 Their movement around the eye, in rare instances, the 
simple removal is made more difficult by unwanted 
migration of the insert to the upper fornix; 
 The occasional unintentional loss during sleep or while 
rubbing the eyes; 
 Their interference with vision, and 
 Difficult placement of the ocular inserts (and removal, 
for insoluble types). 
 
CLASSIFICATION OF OCULAR INSERTS: 
On the basis of their physic-chemical behavior, the inserts 
have been classified, as soluble (S) or insoluble (I). Only the 
latter types can usually deliver drugs by a variety of methods 
at a controlled, predetermined rate, but need removal from 
the eye when ‘empty’. Soluble(S) inserts, also generally 
defined by some authors16as erodible (E), are monolytic 
polymeric devices that undergo gradual dissolution while 
releasing the drug, and do not need removal. It should be 
pointed out that, as indicated in the article by Saettone17, the 
terms ‘soluble’ and ‘erodible’ are not interchangeable, and 
correspond to distinct chemical processes, even if a clear-cut 
distinction between the two mechanisms is sometimes 
difficult. True dissolution occurs mainly through polymer 
swelling, while erosion corresponds to a chemical or 
enzymatic hydrolytic process18. 
Hence, ocular inserts are classified as given below: 
I. Insoluble ocular inserts. 
II. Soluble ocular inserts. 
III. Bio-erodible ocular inserts. 
 
 
FIG. 1: Classification of Ocular Inserts. 
 
I. SOLUBLE OCULAR INSERTS: 
Soluble inserts resemble to the oldest class of ocular inserts, 
which offer the advantage of being wholly soluble, so they 
need not be removed from the site of application, thus, 
limiting the interventions to insertion only 19,20.They are 
further categorized: 
 Based on natural polymers, for example, collagen. 
 Based on synthetic or semi-synthetic polymers20. 
A. Natural polymers: 
The first type of soluble inserts based on natural polymer 
which is used to produce soluble ophthalmic inserts is 
preferably collagen 20.The therapeutic agent is absorbed by 
soaking the insert in a solution containing the drug, and 
drying and rehydrating it before use in the eye. The amount 
of drug contained will depend upon the capacity of the 
binding agent, concentration of the drug solution into which 
the insert is soaked, and the duration of soaking19. As the 
collagen dissolves, the drug is gradually released from the 
interstices between the collagen molecules 2.The soluble 
ophthalmic inserts are easily processed by conventional 
methods viz slow evaporating extrusion, compression or 
injection molding. The release of the drug takes place when 
tears penetrate into the insert. This induces drug release by 
means of diffusion and forms a layer of gel around the core of 
the insert. This gelification causes further release of the drug, 
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but it is still controlled by diffusion. The release rate, J, is 
derived from Fick's law, which yields the following 
expression21: 
J=
     
 
 
When A - Surface are of the membrane. 
K – Diffusion coefficient of the drug 
L – Membrane thickness 
CS – Drug solubility in water 
D – Diffusion coefficient of the Ocusert membrane. 
Since all the terms on the right hand side of the above 
equation are constant, so is the release rate of the device22. 
B. Synthetic and semi-synthetic polymer: This type of 
soluble insert is usually based on synthetic polymers like 
polyvinyl alcohol or on semi-synthetic polymers (e.g., 
cellulose derivatives). A decrease of release rate can be 
obtained by using Eudragit, a polymer normally used for 
enteric coating, as a coating agent of the insert. Saettone et al 
23 have observed in rabbits that Eudragit coated inserts 
containing pilocarpine induced a miotic effect of a longer 
duration, compared to the corresponding uncoated ones. 
However, the inherent problems encountered with these 
soluble inserts are the rapid penetration of the lachrymal 
fluid into the device, the blurred vision caused by the 
solubilization of insert components and the risk of expulsion 
due to the initial dry and glassy consistency of the device24. 
In order to decrease the deformation of the insert and thus to 
prevent blurred vision Ethyl cellulose, a hydrophobic 
polymer, can be used. As for the risk of expulsion, several 
authors have incorporated carbomer, a strong but well 
tolerated bio-adhesive polymer. 
 
Table 1: Components of Soluble Inserts Containing Synthetic Polymers20, 25 
Soluble synthetic 
polymers 
Cellulose derivatives – Hydroxypropyl cellulose, methylcellulose, and hydroxyethyl cellulose  
Divers – Polyvinyl alcohol, ethylene vinyl acetate copolymer. 
Additives Plasticizer – Polyethylene glycol, glycerin, propylene glycol 
Enteric coated polymer – Cellulose acetate phthalate, hydroxypropyl methyl cellulose phthalate. 
Complexing agent – Polyvinylpyrrolidone. 
Bioadhesives – Polyacrylic acids 
 
I. Insoluble Ocular Inserts: Inserts made up of insoluble 
polymer can be classified into two categories: 
A. Reservoir systems; B. Matrix systems 2. 
A. Reservoir Systems: Each class of inserts shows different 
drug release profiles. The reservoir systems can release drug 
either by means of diffusion or by an osmotic process. It 
contains, respectively, a liquid, a gel, a colloid, a semisolid, a 
solid matrix, or a carrier containing drug. Carriers are made 
of organic, hydrophilic, hydrophobic, natural or synthetic 
polymers. They have been sub-classified into: 
1. Diffusional inserts, e.g., ‘Ocuserts’;  
2. Osmotic inserts. 
1. Diffusional insert or Ocuserts: Ocusert system, a novel 
ocular drug delivery system is based on porous membrane. 
The release of drug from diffusional inserts/Ocusert is based 
on a diffusional release mechanism. It consists of a central 
reservoir of drug enclosed in specially designed microporous 
membrane allowing the drug to diffuse from the reservoir at 
a precisely determined rate2. 
As pointed out by Urquhart,26 the Ocusert pilocarpine ocular 
therapeutic system, developed by Alza Corporation, is 
notable for several reasons. This product was the first rate-
controlled, rate specified pharmaceutical for which the 
strength is indicated on the label by the rate(s) of drug 
delivery in vivo, rather than by the amount of contained drug. 
It provides predictable, time-independent concentrations of 
drug in the target tissues, which is otherwise impossible to 
achieve with conventional, quantity-specified, pulse entry 
ophthalmic medications. The near-constant drug 
concentration in ocular tissues markedly improves the 
selectivity of action of pilocarpine. A major advantage is that 
reduction of intraocular pressure (IOP) in glaucoma patients 
is fully maintained while two disturbing side effects of the 
drug, miosis and myopia, are significantly reduced. 
 Pilo-20 and Pilo- 40 are the two types of Ocusert are 
available. The former delivers the drug at a rate of 20 μg/h 
for 7 days, and the latter at a rate of 40 μg/h for 7 days. 
Briefly, it consists of a reservoir containing pilocarpine 
alginate enclosed above and below by thin EVA (ethylene-
vinyl acetate) membranes. The insert is encircled by a 
retaining ring of the same material, impregnated with 
titanium dioxide. The dimensions of the elliptical device are 
(for the 20 μg/h system): major axis-13.4 mm, minor axis-5.7 
mm, thickness-0.3 mm. The membranes are the same in both 
systems, but to obtain a higher release rate, the reservoir of 
the 40 μg/h system contains about 90mg of di (2-ethylhexyl) 
phthalate as a flux enhancer 27. 
 
Table 2: Components of Diffusional Inserts20,25 
Central reservoir Glycerin, ethylene glycol, propylene glycol, water, methyl cellulose mixed with water, 
sodium alginate, poly (vinyl pyrrolidone), poly or ethylene stearate. 
 
Micropores membrane 
 
Polycarbonates, polyvinyl chloride, 
polysulfones, cellulose esters, crosslinked 
poly (ethyl oxide), cross-linked 
polyvinylpyrrolidone, and cross-linked 
polyvinyl alcohol. 
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FIG. 2: Diffusional Inserts27 
 
2. Osmotic inserts: The osmotic inserts are generally 
composed of a central part surrounded by a peripheral part 
and are of two types: 
Type 1: The central part is composed of a single reservoir of 
a drug with or without an additional osmotic solute 
dispersed throughout a polymeric matrix, so that the drug is 
surrounded by the polymer as discrete small deposits. The 
second peripheral part of these inserts comprises a covering 
film made of an insoluble semi-permeable polymer. The 
osmotic pressure against the polymer matrix causes its 
rupture in the form of apertures, through which drug is 
released from the deposits near the surface of the device. 
Type 2: The central part is composed of two distinct 
compartments. The drug and the osmotic solutes are placed 
in two separate compartments, the drug reservoir being 
surrounded by an elastic impermeable membrane and the 
osmotic solute reservoir by a semi-permeable membrane. 
The second peripheral part is similar to that of type 1. The 
tear diffuses into the osmotic compartment inducing an 
osmotic pressure that stretches the elastic membrane and 
contracts the compartment including the drug, so that the 
active component is forced through the single drug release 
aperture28.
 
Table 3: Components of Osmotic Inserts20,25 
Water 
permeable 
matrix 
Ethylene - vinyl esters copolymers, 
Divers- plasticized polyvinyl chloride (PVC), 
polyethylene, cross-linked polyvinylpyrrolidone(PVP) 
Semi permeable 
membrane 
Cellulose acetate derivatives, Divers – Ethyl vinyl acetate (EVA), polyesters of acrylic and 
methacrylic acids (Eudragit ®). 
Osmotic agents Inorganic – magnesium sulfate, sodium chloride, potassium phosphate dibasic sodium carbonate 
and sodium sulfate. 
Organic- calcium lactate, magnesium succinate and tartaric acid. 
Carbohydrates – Sorbitol, mannitol, glucose and sucrose. 
 
B. Matrix Systems: The second category, matrix system, is a 
particular group of insoluble ophthalmic devices mainly 
represented by contact lenses. It comprises of covalently 
cross-linked hydrophilic or hydrophobic polymer that forms 
a three dimensional network or matrix capable of retaining 
water, aqueous drug solution or solid components. The 
hydrophilic or hydrophobic polymer swells by absorbing 
water. The swelling caused by the osmotic pressure of the 
polymer segments is opposed by the elastic retroactive 
forces arising along the chains or cross links are stretched 
until a final swelling (equilibrium) is reached 2. 
Contact Lenses: Contact lenses are shaped structures, 
initially used for vision correction. Their use has been 
extended as potential drug delivery devices by presoaking 
them in drug solutions. The main advantage of this system is 
the possibility of correcting vision and releasing drug 
simultaneously. Contact lenses coated with drugs can absorb 
on its surface water-soluble substances, released after 
applying the drug over the eyeball for a longer period of 
time. The first and most widely used polymer in the 
production of lenses was the cross-linked poly (2-
hydroxyethyl methacrylate) with small amount of ethylene 
glycol dimethylacrylic acid (EGDM) or poly (vinyl 
pyrrolidone) 29,30. Poly (vinyl pyrrolidone) is used for 
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increasing water of hydration, while EGDM is used to 
decrease the water of hydration 2. In recent years, research 
has been conducted on employing silicon-based lenses 31–34. 
Interest in contact lenses still grows, which is confirmed by 
increase in the number of articles on its use published in 
recent years. Examples of drugs whose pharmaceutical 
availability from lenses was researched include timolol 31, 
ciprofloxacin 32, dexamethasone 33, and cyclosporine 34. 
Peng and Chauhan developed a new delivery system for 
Cyclosporin- A delivery for the purpose of Dry eye syndrome 
(DES) treatment using Vitamin- E-loaded silicone-hydrogel 
contact lenses. ACUVUE OASYS lenses were selected due to 
the drug release profiles and loaded with Vitamin E. The 
results showed that Vitamin-E-loaded lenses can provide 
Cyclosporin- A release within the therapeutic window for a 
period of about a month. It is a promising delivery system 
though that in vivo release and toxicity studies are required 
35. 
Types of Contact Lenses: 
Refojo36 has proposed a subdivision of contact lenses into 5 
groups. 
a) Rigid 
b) Semi-rigid 
c) Elastomeric 
d) Soft hydrophilic 
e) Bio-polymeric 
Rigid contact lenses have the disadvantage of being 
composed of polymers (e.g., poly methyl methacrylic acid) 
hardly permeable to moisture and oxygen, a problem which 
has been overcome by using gas permeable polymers such as 
cellulose acetate butyrate. However, these systems are not 
suitable for prolonged delivery of drugs to the eye and their 
rigidity makes them very uncomfortable to wear. For this 
reason, soft hydrophilic contact lenses were developed for 
prolonged release of drugs. The soft hydrophilic contact 
lenses are very popular because they are easy to fit and are 
tolerated better. The drug incorporation into contact lenses 
depends on whether their structure ishydrophilic or 
hydrophobic. When contact lens (including 35 to 80% water) 
issoaked in solution, it absorbs the drug. Drug release 
depends markedly on the amount of drug, the soaking time 
of the contact lens and the drug concentration in the soaking 
solution 2, 28. 
 
 
FIG. 3: Ocular Lens27 
 
III. Bioerodible Ophthalmic Inserts: They are formed by 
bio-erodible polymers (e.g., polyester derivatives, cross-
linked gelatin derivatives) which undergo hydrolysis of 
chemical bonds and hence dissolution. The great advantage 
of these bio-erodible polymers is the possibility of 
modulating their erosion rate by modifying their final 
structure during synthesis and by addition of anionic or 
cationic surfactants. A cross-linked gelatin insert was used to 
increase bioavailability of dexamethasone in the rabbit eye. 
The dexamethasone levels were found to be four-fold greater 
in the aqueous humor compared to a dexamethasone 
suspension. However, erodible systems can have 
significantly variable erosion rates based on individual 
patient physiology and lachrymation patterns, while 
degradation products and residual solvents used during the 
polymer preparation can cause inflammatory reaction. Some 
important ocular inserts which are available commercially 
are soluble ophthalmic drug inserts (SODI) while others are 
in the advanced stages of development like collagen shield, 
ocufit, new ophthalmic delivery system (NODS) and minidisc 
12. 
POLYMERIC SYSTEMS EMPLOYED IN THE 
FORMULATION OF OCULAR INSERTS:  
Polymers used in ocular inserts can be of natural, synthetic 
or semi synthetic in nature. Further, they can be either water 
soluble polymers with linear chains or water insoluble 
polymers joined by cross linking agents. Most commonly 
used polymer groups include nonionic polymer like 
hydroxypropyl methyl cellulose (HPMC); polycationics like 
chitosan, DEAE-dextran and polyanionics like polyacrylic 
acid (PAA) derivatives e.g. carbopols, polycarbophils, 
carboxy-methylcellulose. Some of the polymers used in 
ocular inserts are given in Table 4. 
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Table 4: Commonly Used Polymers in Ocular Inserts9 
Cellulose 
polymers 
Cellulosic polymers such as methyl cellulose; hydroxyethylcellulose (HEC); hydroxypropylmethylcellulose 
(HPMC); hydroxypropylcellulose (HPC) were introduced as viscolizers into artificial tear preparations to 
retard canalicular drainage and improve contact time. All cellulose-ethers impart viscosity to the solution, 
have wetting properties and increase the contact time by virtue of film forming properties.  Drug release 
was found to be better in terms of extent and amount. Controlled release has been observed with various 
beta-blockers from HPM inserts with improved ocular bioavailability and reduced toxicity and dosing 
frequency. HPC, HPMC, PVP and PVA were also used in different ratios to prepare the ocular films with the 
objective to reduce the frequency of drug administration, patient compliance, controlled drug release and 
greater therapeutic efficacy for ocular infections such as conjunctivitis, keratitis, kerato-conjunctivitis and 
corneal ulcers. 
Polyvinyl 
Alcohol (PVA) 
PVA was introduced into ophthalmic preparations and reported to have a superior corneal contact time. 
PVA lowers the surface tension of water reducing interfacial tension at an oil/water interface and 
enhances tear film stability. This film-forming property together with ease of sterilization, compatibility 
with a range of ophthalmic drugs and an apparent lack of epithelial toxicity lead to use of PVA as a drug 
delivery vehicle and artificial tear preparation. Polyvinyl alcohol (PVA) has been used as a carrier to 
formulate polymeric inserts and were found to enhance bio-availability in comparison to solutions. 
Poly (ethylene 
oxide) [PEO] 
Poly Ethylene Oxide (PEO) exhibits good compressibility and thus is easy for the manufacturing of matrix 
tablets. In contact with an aqueous medium, poly (ethylene oxide) hydrates and gels superficially, the 
polyether chains of PEO forming strong hydrogen bonds with water. Drug release from poly (ethylene 
oxide) matrices is controlled by polymer swelling and erosion, or drug diffusion through the gel, or by 
both processes. Various release patterns can be achieved depending on the poly (ethylene oxide) 
molecular mass and physicochemical properties of the drug. Good mucoadhesive properties and lack of 
irritancy to the rabbit eye has been reported. It points that this polymer can be an interesting candidate 
material for controlled release erodible ocular inserts. 
Pluronics, 
Poloxamer 
F127 
Sustained drug delivery can also be achieved by use of a polymer that changes from solution to gel at the 
temperature of the eye (33 to 34o C). An example of this type of polymer is poloxamer F127, which 
consists of linked polyoxyethylene and polyoxypropylene units. At room temperature, the poloxamer 
remains as a solution. When the solution is instilled onto the eye surface, the elevated temperature causes 
the solution to become a gel, thereby prolonging its contact time with the ocular surface. 
Collagen Collagen is widely used for biomedical applications. It accounts for about 25 % of the total body protein in 
mammals and is the major protein of connective tissue, cartilage and bone. Importantly, the secondary 
and tertiary structures of human, porcine, and bovine collagen are very similar, making it possible to use 
animal-sourced collagen in the human body. Collagen shields are designed to be sterile, disposable, 
temporary bandage lenses that conform to the shape of the eye and protect the cornea. Their dissolution 
time on cornea ranges from 12-17 hours and is controlled by varying degree of cross-link of the polymer. 
Eudragit The polymer system avoids of any irritant effect on cornea, iris and conjunctiva up to 24 hours after 
application and seems to be a suitable inert carrier for ophthalmic drug. Similarly, In another study, 
Eudragit RL100 polymer nanoparticle system loaded with cloricromene polymer matrix was prepared 
and characterized on the basis of physicochemical properties, stability and drug release features by 
topical administration in the rabbit eye and was compared with an aqueous solution of the same drug. 
Poly (Lactic 
Acid) / Poly 
(Glycolic Acid ) 
Polymers such as poly (lactic acid) or poly (glycolic acid) undergo hydrolytic degradation in the body and 
become monomers of lactic acid or glycolic acid. These monomers can be metabolized and eliminated 
from the tissues. It is possible to incorporate drugs in the matrix of these polymers. The polymer 
containing the drug releases the drug for a sustained period and undergoes degradation simultaneously. 
These polymers have been used as materials of absorbable surgical sutures for many years and proved to 
be safe and biocompatible. Feasibility of delivering drugs to the retina and vitreous as well as the 
subconjunctival space using the microspheres of biodegradable polymers has been reported. 
Alginate and 
derivatives 
Alginate is a linear co-polysaccharide isolated from brown seaweeds and certain bacteria. Chemically it is 
a (1-4)-linked block copolymer of â-D-mannuronate (M) and its C-5 epimer R-L-guluronate (G), with 
residues arranged in homopolymeric sequences of both types and in regions which approximate to the 
disaccharide repeating structure (MG). Commercially, alginate is widely used as a gelling agent not only in 
foods but also in other industries such as pharmaceutical, biomedical, and personal care). As it is easy to 
prepare alginate ionotropic gels at mild conditions, it is possible to entrap drugs and living cells in 
alginate gels, which allow a wide application of alginate as scaffolds for tissue engineering, drug delivery 
systems, and cell encapsulation and transplantation. Drug release from such matrices may be controlled 
by polymer swelling or erosion or drug diffusion in hydrated gel or by these processes all together. All 
these properties and applications are ultimately dependent on the molecular architecture and gelling 
mechanism. Recently alginate-chitosan ocular inserts has been studied as an efficient means of delivering 
antibiotics (gatifloxacin). 
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OCULAR INSERT DEVICES: 
The various types of inserts available or in development are presented in Table 5.  
Table 5: Ocular Insert Devices 2,12,37 
Name Reported By Description 
Soluble ocular 
drug Insert (SODI) 
Khromow et al. 
Small oval wafer, composed of soluble copolymers consisting of actylamide, N-
venyl pyrrolidone and ethyl acetate, softens on insertion. 
New ophthalmic 
drug delivery 
system 
Lloyd et al. 
Medicated solid polyvinyl alcohol flag that is attached to a paper- covered with 
handle. On application, the flag detaches and gradually dissolves, releasing the 
drugs. 
Collagen shields 
Bloomfield et 
al. 
Erodible disc consisting of cross-linked porcine scleral collagen, used as tear 
substitiue and for the delivery of gentamicin. 
Ocusert Quigley et al. 
Flat, flexible elliptical insoluble device consisting of two layers, enclosing a 
reservior, used commercially to deliver Pilocarpine for 7 days. 
Minidisc ocular 
therapeutic system 
Bewa et al. 
This monolytic polymeric device, originally described by Bawa et al. (Bausch and 
Lomb, Rochester, New York) and referred to as Minidisc ocular therapeutic system 
(OTS), is shaped like a miniature (diameter 4-5 mm) contact lens, with a convex 
and a concave face, the latter conforming substantially to the sclera of the eye. The 
particular size and shape reportedly allow an easy placement of the device under 
the upper or lower lid without compromising comfort, vision or oxygen 
permeability. 
Lacrisert Lamberts et al. 
Rod-shaped device made from Hydroxy propyl cellulose used for the treatment of 
dry eye syndrome as an alternative to tears. 
One-side-coated 
ocular insert 
Sasaki et al. 
Prepared by attaching a polypropylene tape on the one side of the polymer disc of 
poly (2-hydroxypropylmethacrylate) (HPM) containing Tilisolol as a model 
ophthalmic drug. 
Bioadhesive 
ophthalmic drug 
insets (BODI) 
Gurtler et al. 
Adhesive rods based on a mixture of Hydroxy propyl cellulose, ethyl cellulose, Poly 
acrylic acid and cellulose acetate phthalate 
Silicone rubber/ 
hydrogel composite 
ophthalmic inserts 
Chetoni et al. 
A cylindrical device containing mixtures of silicone elastomer and sodium chloride 
as a release modifier with a stable polyacrylic acid (PAA) or polymethylacrylic acid 
(PMA) interpenetrating polymer network grafted on to the surface. 
 
Dry drops 
 
Diestelhorst et 
al. 
A preservative free of hydrophilic polymer solution that is freeze dried on the tip of 
a soft hydrophobic carrier strip, immediately hydrate in tear strip 
Molecularly 
imprinted soft 
contact lenses 
Hiratani et al. 
Soft contact lenses consisted of N,N -diethylacrylamide, methacrylic acid and 
ethylene glycol dimethacrylate. Timolol was used as a model drug. 
Gelfoam 
Simamora et 
al. 
Slabs of Gelfoam impregnated with a mixture of drug and cetyl ester wax in 
chloroform. 
New ophthalmic 
mydriatic insert 
Stephane et al. 
New insoluble-matrix retropalpebral ophthalmic insert containing phenylephrine 
and tropicamide. Potential alternative as drug delivery system prior to cataract 
surgery. 
OphthaCoil Pijls et al. 
The ocular insert consists of a pradoß oxacin –loaded adherent hydrogel on a thin 
wire, which is coiled. The inner lumen of the coil was Þ lled with a polymer rod 
made from a poly (2-hydroxyethyl methacrylate) hydrogel and loaded with the 
same drug. 
Gelatin hydrogels 
and lyophilisates 
with potential 
applications as 
ocular inserts 
Madalina et al. 
Hydrogels and lyophilisates were obtained by chemical and lyophilisates 
crosslinking of gelatin using N-hydroxysuccinimide and N,N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride. Pilocarpine 
hydrochloride was used as a model drug. 
Mucoadhesive 
ocular insert 
Hornof et al. 
The inserts tested were based either on unmodified or thiolated poly (acrylic acid) 
for the controlled delivery of ophthalmic drugs and to evaluate its efficacy in vivo. 
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EVALUATION OF OCULAR INSERTS: 
A. Universal Tests for Ophthalmic Pharmaceuticals: 
1. Description: The test often called appearance on a 
specification is a qualitative description of the ophthalmic 
pharmaceuticals. For example, the description of ophthalmic 
preparations on a specification may read: 
transparent/opaque preparation, proper labeling, imprinted 
with ‘‘Rx’’38 
2. Identification: The purpose of this test is to verify the 
identity of the active pharmaceutical ingredient (API) in the 
ophthalmic pharmaceuticals. This test should be able to 
discriminate between compounds of closely related 
structures that are likely to be present38. 
3. Assay: This test determines the strength or content of the 
API in the ophthalmic pharmaceuticals and is sometimes 
called a content test38. 
4. Impurities: This test determines the presence of any 
component that is not the API or an excipient of ophthalmic 
pharmaceuticals. The most common type of impurities that 
are measured is related substances, which are processed 
impurities from the new drug substance synthesis, 
degradation products of the API, or both38. 
B. Quality Control Test Procedures for Ocular Inserts as 
Per IP, BP and USP: 
1. Uniformity of dosage units: Dosage units are defined as 
dosage forms containing a single dose or part of a dose of an 
active substance in each dosage unit. To ensure the 
consistency of dosage unit, each unit in a batch should have 
active substance content within a narrow range around the 
label claim. Unless otherwise stated, the uniformity of 
dosage unit specification is not intended to apply to 
suspensions, emulsions or gels in single dose containers 
intended for cutaneous administration. The term ‘uniformity 
of dosage unit’ is defined as the degree of uniformity in the 
amount of the active substance among dosage units. The test 
of mass variation is applicable for the following dosage 
forms: 
 Solutions enclosed in single dose containers and in soft 
capsules 
 Solids (including powders, granules and sterile solids) 
that are packed in single-dose containers and contain 
no added active or inactive substances 39.  
2. Content uniformity: Select not less than 30 units, and 
proceed as follows for the dosage form designated. For solid 
dosage forms like powders assay 10 units individually using 
an appropriate analytical method. Calculate the acceptance 
value (AV) using the equation 1; 
|M-X| + ks……………. (1) 
Where, 
 X = mean of individual contents(x1, x2……..xn) expressed as 
a percentage of the label claim. 
M= reference value 
k = acceptability constant 
s = sample standard deviation 
Single-dose powders for eye drops and eye lotions comply 
with the test or, where justified and authorized, with the 
tests for uniformity of content and/or uniformity of mass. 
Herbal drugs and herbal drug preparations present in the 
dosage form are not subject to the provisions of this 
paragraph 39. 
 
3. Uniformity of content: The test for uniformity of content 
of single dose preparation is based on the assay of the 
individual contents of active substance of a number of single 
dose units to determine whether the individual contents are 
within the limits set with reference to the average contents 
of the sample. Using the suitable analytical method, 
determine the individual contents of the active substances of 
10 dosage units taken at random 39.  
BP USP 
      TESTS        I.P      B.P         U.S.P 
Uniformity of dosage units Not specified specified Not specified 
Content uniformity Not specified specified Not specified 
 
OTHER TESTS: 
Swelling Index: Different swelling degree is exhibited by 
Hydrophilic polymers of different structures, depending on 
relative resistance of matrix network structure to water 
particles’ movement. Polymer chains exhibiting low ability to 
form hydrogen bonds may not be able to form strong 
network structure, resistant to fast water penetration. The 
bigger the strength and number of hydrogen bonds between 
polymer chains are, the slower the water particles diffuse 
into the hydrated matrix. Swelling of the polymer is vital to 
activation of bio-adhesive abilities, which activate just after 
swelling begins. With the growth of polymer hydration, the 
adhesion grows until the moment when excessive hydration 
leads to sudden fall of adhesion strength, which is an effect of 
the untangling of outer polymer layer. The degree and speed 
of insert hydration, as well as swelling, affect drug release 
from a dosage form. Therefore, this parameter is of greatest 
significance for drug release prediction and bio-adhesive 
matrix potential. Swelling examination is performed to 
measure bulk hydrophilicity and polymer hydration. In the 
procedure, a specified number of inserts are chosen, 
weighed, and put separately in beakers containing a solution 
simulating tear fluid, physiological saline buffered with 
phosphates, or distilled water at fixed temperature, for 
example, 32∘C ± 0.5∘C. In specified time intervals, inserts are 
taken out, dried with filter paper, and weighed once more. 
The procedure is repeated until the moment when mass 
growth is not observed anymore40. 
The degree, to which the liquid is taken up, called the 
swelling index, is calculated from the formula40: 
Swelling index =[
(     )
  
]       
Where, 𝑊o is the initial sample weight and 𝑊𝑡is the sample 
weight at 𝑡time. 
Examinations of Moisture Absorption and Loss: These 
examinations are performed in order to assess physical 
stability and integrity of inserts’ polymer matrix in dry 
conditions and at raised moisture. For moisture absorption 
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examination, a specified number of inserts are chosen and 
placed in desiccator, in which high moisture level, for 
example, 75 ± 5% RH, is maintained. After a specified time 
period, inserts are taken out and weighed again, and the 
percentage moisture absorption is calculated from the 
formula 40: 
% Moisture Absorption = 
(                          ) 
             
     
In moisture loss examination, a chosen number of inserts are 
put in desiccator containing anhydrous calcium chloride, 
which ensures dry conditions inside the container. After a 
suitable time period, inserts are taken out and weighed 
again, and the percentage moisture loss is calculated from 
theformula40: 
% Moisture Loss =
(                          ) 
             
     
Thickness of film: Film thickness is measured by using the 
Dial caliper at different points of the formulation and the 
mean value is calculated 27. 
Accelerated stability studies: The accelerated stability 
studies are carried out to predict the degradation that occurs 
over prolonged periods of storage, at normal conditions. The 
films of the insert are taken in a separate petri dish and are 
kept at three different temperatures 400°C, 500°C, and 
600°C, and the time taken for degradation of the ocular 
inserts is checked 41, 42. 
Test for sterility: It is done for detecting the presence of 
viable forms of microorganisms in the preparation. The 
working conditions should be monitored regularly by taking 
the samples of air and surface of the working area, and there 
should not be any cross contamination. The test is based on 
the principle that if the nutrient media is provided to the 
microorganisms and they are kept in a favorable condition of 
temperature, the microorganisms will grow and their 
presence is indicated by the turbidity in medium. The batch 
size taken for sterility testing in case of ophthalmic and other 
non-injectable preparations is given in Table 6. 
 
Table 6: Consistent with USP, JP and BP, Minimum Number of Articles to be Tested in Relation to the Number of 
Articles in the Batch38, 43 
Not more than 200 containers 5% or two containers, whichever is greater. 
More than 200 containers 10 containers. 
Not more than 100 containers* 10% or 4 containers, whichever is greater. 
More than 100 but not more than 500 containers** 10 containers. 
More than 500 containers*** 2% or 20 containers, whichever is less. 
“**” If the product is presented in the form of single-dose containers. 
“**” If the batch is not known, use the maximum number of items prescribed. 
“***” If the contents of one container are enough to inoculate the 2 media, this column gives thenumber of containers 
needed for both the media together. 
 
CONCLUSION:  
The main efforts in ocular drug delivery during the last few 
years has been on the design of systems which will prolong 
the residence time of topically applied drugs in the 
conjuctival sac and will improve patient compliance. Various 
newer approaches like ocular inserts as discussed in this 
article have been found promising. However, further 
research is needed in this field in order to overcome the 
drawbacks still associated with these types of drug delivery 
systems. 
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